SELONSERTIB



NAME OF DRUG : SELONSERTIB

ALSO KNOWN AS : GS-4997

LABORATORY : GILEAD

STATUS AND ADVANCEMENT

Type of drug : (ASK1) inhibitor

Clinical trials advancement : Recruiting Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated time to market : 36 months.

LABORATORY ABSTRACT ON THE DRUG

Selonsertib is an investigational small molecule inhibitor of ASK1, a protein that promotes inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH.

RECENT NEWS ON SELONSERTIB

2016-11-14 : Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016

SOME PUBLICATIONS RELATED WITH SELONSERTIB

September 2017 : The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial

July 2017 : Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease

April 2017 : Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects

April 2017 : Treatment with Selonsertib, an Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1), Reduces Hepatic Phospho-p38 Expression and Markers of Hepatocellular Apoptosis and Necrosis in Patients with NASH

November 2016 : The Pharmacokinetics of GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1), in Subjects with Mild, Moderate, and Severe Hepatic Impairment

June 2016 : Apoptosis signal-regulating kinase 1 exhibits oncogenic activity in pancreatic cancer

October 2012 : Therapeutic targets in the ASK1-dependent stress signaling pathways

April 2010 : Abstract 1201: Inhibition of ASK1 through phosphorylation of serine 967 by PI3K/Akt-mediated pathways

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SELONSERTIB


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE